^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Valchlor (mechlorethamine gel)

    i
    Other names: topical nitrogen mustard, nitrogen mustard topical gel
    Associations

    News

    Trials
    Company:
    Helsinn, Juniper Bio, Recordati
    Drug class:
    Alkylating agent
    Related drugs:
    Associations

    News

    Trials
    4ms
    SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY) (clinicaltrials.gov)
    P=N/A, N=840, Recruiting, Leiden University Medical Center | Not yet recruiting --> Recruiting
    Enrollment open • HEOR • Real-world evidence
    |
    Valchlor (mechlorethamine gel)
    4ms
    Topical Chlormethine Gel in the Treatment of Lymphomatoid Papulosis: A Case Report and Literature Review. (PubMed, J Clin Med)
    Six months post-treatment, the patient remained in remission. This case underscores the effectiveness of CG in achieving sustained remission in acral LyP, suggesting its potential as a treatment option for this rare condition.
    Journal
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 positive
    |
    Mustargen (mechlorethamine) • Valchlor (mechlorethamine gel)
    5ms
    FIL_CLOR-CTCL: Long-term Assessment of Chlormethine Gel in Mycosis Fungoides (clinicaltrials.gov)
    P=N/A, N=190, Not yet recruiting, Fondazione Italiana Linfomi - ETS
    New trial
    |
    Valchlor (mechlorethamine gel)
    6ms
    SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY) (clinicaltrials.gov)
    P=N/A, N=840, Not yet recruiting, Leiden University Medical Center
    New trial • HEOR • Real-world evidence
    |
    Valchlor (mechlorethamine gel)
    1year
    StrataCTX® As a Steroid Sparing Device (clinicaltrials.gov)
    P=N/A, N=70, Recruiting, Columbia University | Trial completion date: Jul 2024 --> Aug 2026 | Trial primary completion date: Jul 2024 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    Valchlor (mechlorethamine gel)
    over1year
    HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL (clinicaltrials.gov)
    P2, N=10, Completed, Soligenix | Recruiting --> Completed
    Trial completion
    |
    HyBryte (synthetic hypericin) • Valchlor (mechlorethamine gel)
    over1year
    GR-CTCL_CL: The Mechanism of Action of Chlormethine (CL) Gel in the Treatment of MF-CTCL Adult Patients (clinicaltrials.gov)
    P=N/A, N=40, Recruiting, National and Kapodistrian University of Athens
    New trial
    |
    Valchlor (mechlorethamine gel)
    almost2years
    HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL (clinicaltrials.gov)
    P2, N=10, Recruiting, Soligenix | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HyBryte (synthetic hypericin) • Valchlor (mechlorethamine gel)
    2years
    HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL (clinicaltrials.gov)
    P2, N=10, Not yet recruiting, Soligenix
    New P2 trial
    |
    HyBryte (synthetic hypericin) • Valchlor (mechlorethamine gel)
    2years
    Interstitial fluid immunophenotyping characterizes topical chlormethineinduced changes in the tumor micro-environment in early-stage mycosis fungoides. (ISDS 2023)
    In this exploratory, open-label, deep phenotyping trial a total of 21 early-stage (IA – IIA) MF patients were treated with chlormethine gel 160μg/g QD for 16 weeks...We show for the first time the feasibility of suction blister fluid analysis to investigate TME in MF patients. These results suggest that CD8+HLA-DR+ cytotoxic and regulatory T-lymphocytes have a prominent role in disease improvement with chlormethine therapy in MF.
    CD8 (cluster of differentiation 8) • CD14 (CD14 Molecule) • CD68 (CD68 Molecule)
    |
    Valchlor (mechlorethamine gel)
    2years
    Topical chlormethine induces tumor micro-environment shift in early-stage mycosis fungoides by interstitial fluid immunophenotyping. (EADV 2023)
    Materials & In this exploratory, open-label, deep phenotyping trial a total of 21 early-stage (IA – IIA) MF patients were treated with chlormethine gel 160µg/g QD for 16 weeks... We show for the first time the feasibility of suction blister fluid analysis to investigate TME in MF patients. These results suggest that CD8+HLA-DR+ cytotoxic and regulatory T-lymphocytes have a prominent role in disease improvement with chlormethine therapy in MF.
    Late-breaking abstract
    |
    CD8 (cluster of differentiation 8) • CD14 (CD14 Molecule) • CD68 (CD68 Molecule)
    |
    Valchlor (mechlorethamine gel)
    2years
    REACH: Study to Determine the Aetiology of Chlormethine Gel Induced-skin Drug Reaction in Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL) (clinicaltrials.gov)
    P2, N=2, Terminated, European Organisation for Research and Treatment of Cancer - EORTC | N=100 --> 2 | Trial completion date: May 2028 --> Apr 2023 | Recruiting --> Terminated | Trial primary completion date: May 2025 --> Apr 2023; After an extensive assessment of the study feasibility, it was decided to discontinue the clinical trial due to poor recruitment.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    CD4 (CD4 Molecule) • CD7 (CD7 Molecule) • DPP4 (Dipeptidyl Peptidase 4)
    |
    Valchlor (mechlorethamine gel)